AbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results for ABCL635, Demonstrating Significant Reduction in Frequency and Severity of Vasomotor Symptoms and a Favorable Tolerability Profi
Go back to AbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results for ABCL635, Demonstrating Significant Reduction in Frequency and Severity of Vasomotor Symptoms and a Favorable Tolerability Profi| (NASDAQ: ABCL) | Delayed: 9.34 +2.41 (34.78%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $6.93 | 52 Week High | $ | |||
| Open | $8.76 | 52 Week Low | $ | |||
| Day High | $10.01 | P/E | N/A | |||
| Day Low | $8.40 | EPS | $ | |||
| Volume | 46,022,181 | |||||
